5/29
07:59 am
akya
We Think Some Shareholders May Hesitate To Increase Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO Compensation [Yahoo! Finance]
Low
Report
We Think Some Shareholders May Hesitate To Increase Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO Compensation [Yahoo! Finance]
5/23
05:03 pm
akya
NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! F
Low
Report
NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! F
5/14
02:27 pm
akya
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $10.00 to $6.00. They now have a "buy" rating on the stock.
Low
Report
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $10.00 to $6.00. They now have a "buy" rating on the stock.
5/14
01:31 pm
akya
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at BTIG Research from $9.00 to $6.00. They now have a "buy" rating on the stock.
Low
Report
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at BTIG Research from $9.00 to $6.00. They now have a "buy" rating on the stock.
5/13
06:48 pm
akya
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]
5/13
04:11 pm
akya
Akoya Biosciences Reports First Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Akoya Biosciences Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/13
04:00 pm
akya
Akoya Biosciences Reports First Quarter 2024 Financial Results
High
Report
Akoya Biosciences Reports First Quarter 2024 Financial Results
5/9
10:30 am
akya
Spatial Genomics Market to be Worth $3.23 Billion by 2031 - Exclusive Report by Meticulous Research® [Yahoo! Finance]
Low
Report
Spatial Genomics Market to be Worth $3.23 Billion by 2031 - Exclusive Report by Meticulous Research® [Yahoo! Finance]
5/9
08:12 am
akya
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients [Yahoo! Finance]
Medium
Report
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients [Yahoo! Finance]
5/9
08:00 am
akya
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
Medium
Report
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
5/6
11:53 am
akya
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]
Low
Report
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]
5/6
08:13 am
akya
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts [Yahoo! Finance]
Low
Report
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts [Yahoo! Finance]
5/6
08:00 am
akya
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
Low
Report
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
5/2
08:08 am
akya
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows [Yahoo! Finance]
Low
Report
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows [Yahoo! Finance]
5/2
08:00 am
akya
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
Low
Report
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
4/22
04:05 pm
akya
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
Low
Report
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
4/5
08:08 am
akya
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale [Yahoo! Finance]
Medium
Report
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale [Yahoo! Finance]
4/5
08:00 am
akya
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
Medium
Report
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
3/19
07:06 am
akya
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider [Yahoo! Finance]
Low
Report
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider [Yahoo! Finance]
3/19
07:00 am
akya
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider
Low
Report
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider
3/6
11:58 am
akya
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at JPMorgan Chase & Co. from $12.00 to $10.00. They now have an "overweight" rating on the stock.
Low
Report
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at JPMorgan Chase & Co. from $12.00 to $10.00. They now have an "overweight" rating on the stock.
3/5
10:35 am
akya
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target raised by analysts at UBS Group AG from $7.00 to $7.50. They now have a "buy" rating on the stock.
Medium
Report
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target raised by analysts at UBS Group AG from $7.00 to $7.50. They now have a "buy" rating on the stock.
3/5
10:11 am
akya
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/5
09:11 am
akya
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.
High
Report
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.
3/4
07:08 pm
akya
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]